Our approach
Lorem ipsum sint occaecat cupidatat nondolor sit amet elitase.
Programs
We are harnessing the power of our multi-omic platform to characterize complex diseases and treatments where suspension cells play critical roles, including hematological cancers, immunotherapies, and cell-based therapies.
Hematological cancers exhibit highly elaborate and heterogenous genotypic and cell signaling profiles while featuring limited actionable mutations. Additionally, the tumor microenvironment plays critical roles in the cancer cells’ behavior and response to drugs. By addressing these challenges in patient care and drug development, our approach has the unique potential [rephrase] to deliver powerful clarity of individual patients’ drug response and disease evolution.
Our Approach
Deep phenotypic profiling and functional characterization of suspension cells can be technically challenging due to their susceptibility to physical perturbations. At LynxBio, we drive innovation by combining proprietary, cutting-edge technologies with [established solutions], allowing us to [take] our understanding of factors that drive disease evolution and progression to new levels.
Excepteur sint occaecat cupida
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Daute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Publications
Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications. [SLAS Technology 2019]
Integrating Population Heterogeneity Indices with Microfluidic Cell-Based Assays. [SLAS Discovery 2018]
Multiple Myeloma Cell Drug Responses Differ in Thermoplastic vs PDMS Microfluidic Devices. [J Vis Exp 2017]
Single cell functional analysis of multiple myeloma cell populations correlates with diffusion profiles in static microfluidic coculture systems. [Biomicrofluidics 2016, best paper award]
MicroC3: an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. [Integr Biol 2015, cover article]
Microscale functional cytomics for studying hematologic cancers. [Blood 2012]